Table 1.

Baseline characteristics of all treated patients (N = 33)

Characteristicn or n/N (%)
Age, y
 Median64
 Range50-82
Male sex20 (61)
ECOG performance status ≤132 (97)
Rai stage III-IV9 (27)
Bulky disease ≥5 cm10/32 (31)
β2-microglobulin >3 mg/L21/27 (78)
No. of prior therapies
 Median4
 Range2-13
Ibrutinib as most recent prior therapy*30 (91)
Duration of prior ibrutinib treatment, mo
 Median12
 Range1-62
Time from ibrutinib end to acalabrutinib start, d
 Median47
 Range3-331
Baseline cytopenias
 ANC ≤1.5 × 109/L4 (12)
 Hemoglobin ≤11.0 g/dL9 (27)
 Platelets ≤100 × 109/L13 (39)
Genomic status
 del(11q)7/32 (22)
 del(17p)12/32 (38)
 del(13q)21/27 (78)
TP53 mutation8/27 (30)
NOTCH1 mutation2/27 (7)
SF3B1 mutation4/27 (15)
 Unmutated IGHV25/31 (81)
  • ANC, absolute neutrophil count; ECOG, Eastern Cooperative Oncology Group.

  • * Other most recent prior therapies: venetoclax, n = 1; methylprednisolone with rituximab, n = 1; investigational drug (TG02), n = 1.